Article
A new kind of drug, a Raf kinase inhibitor, is well-tolerated and may prove effective in treating patients with metastatic melanoma, according to researchers from the Abramson Cancer Center of the University of Pennsylvania.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.